Treatment for no-options heart patients with coronary artery disease. Procedure involves the injection into the heart of a protein growth factor that stimulates the growth of new blood vessels around blocked coronary arteries.

Patients with chronic, stable angina with documented coronary artery disease are eligible for the study.

Ages Eligible for Study:  25 Years   -   90 Years,  Genders Eligible for Study:  Both

Criteria

3 month history of chronic, stable angina.

Mini-thoracotomy and anesthesia not contraindicated.

Not eligible for by-pass or PTCA procedures.

One/two/three vessel disease with documentation of greater than 70% narrowing of a major coronary artery, or diffuse coronary artery disease.

Heart ejection fraction >25%.

Normal retinal eye exam.

Subjects must be on conventional medication including one of the following: beta-blockers, calcium entry blockers, long-acting nitrates.

Female subjects must be post-menopausal or sterilized, or if of child-bearing age, not breast-feeding, on contraceptive drugs or devices, and have no intention of becoming pregnant during the course of the study.